Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with brain diseases. For this purpose, Lundbeck is engaged in the research, development, manufacturing, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at the disease areas within psychiatry and neurology.
Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have production facilities in Denmark, France and Italy.
With the first product launched in Chinese market in 1996, Lundbeck, headquartered in Beijing, has officially settled in China since 2007, formally started the commercial operation in China. Our focused four disease areas are depression, schizophrenia, Alzheimer’s Disease and Parkinson’s Disease. We are establishing Lundbeck as a strong and independent CNS leader in China by improving the lives of patients. We stay true to our beliefs: patient-driven, courageous, ambitious, passionate, responsible.
In the past years, Lundbeck China has been dedicated to increase CNS awareness and education in psychiatry and neurology and launched a number of disease education programs and academic exchange projects. Lundbeck is also highly committed to contributing to the development of China’s healthcare career and public hospital reform and supporting the healthcare and hospital management capacity-building and academic exchanges and hopes to eventually serve the continuous improvement of medical treatment quality and patients’ satisfaction.